FREMONT, Calif., March 17 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody
therapeutics, announced today it has filed a resale registration statement on
Form S-3 with the U.S. Securities and Exchange Commission covering its
1.75 percent Convertible Senior Notes due December 2011 and the common stock
issuable upon conversion of the notes. As previously announced, the notes
were issued in a private placement in December 2004. The Company did not
issue any new securities and will not receive any proceeds from the resale of
securities under this registration statement.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid generation,
selection and production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its leadership
position in human antibody technology to build a diversified product portfolio
through its own development efforts and the establishment of collaborations
with multiple pharmaceutical and biotechnology companies. For more information
on Abgenix, visit the company's website at http://www.abgenix.com.
Statements made in this press release about Abgenix's technologies,
product development activities, collaborative arrangements and process science
and manufacturing capabilities, other than statements of historical fact, and
about its projected financial results and the achievement of milestone or
similar payments, are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials, the progress of research and product development programs, product
manufacturing, regulatory approval processes, competitive products and
services, future capital requirements, the extent and breadth of Abgenix's
patent portfolio and other factors set forth in Abgenix's public filings with
the Securities and Exchange Commission, including the risks described in
Abgenix's annual report on Form 10-K for the year ended December 31, 2004.
Abgenix is providing this information as of the date of this press release and
does not undertake any obligation to update any forward-looking statement
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Ami Knoefler, Senior Director of Corporate
Communications and Investor Relations, of Abgenix, Inc.,
+1-510-284-6350, or +1-510-284-6605
|
